REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine phenylacetate) in development for the treatment and prevention of hepatic encephalopathy (HE) will be presented at The Liver Meeting® 2017, the 68 Annual Meeting of the American Association for the Study of Liver Disease (AASLD), October 20-24, 2017, at the Washington Convention Center in Washington, D.C. Select findings from each presentation are cited below. Poster Presentations: Session: Complications of Cirrhosis I Session Date and Time: October 20, 2017 from 8:00 AM to 5:30 PM ET Location: Hall...
|
